Randomized Trial of TAS-102 for Refractory Metastatic Colorectal Cancer
Open accessThe DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Early clinical trials conducted primarily in Japan have shown that TAS-102, an oral agent that combines trifluridine and tipiracil hydrochloride, was effective in the treatment of refractory colorectal cancer. We conducted a phase 3 trial to further assess the efficacy and safety of TAS-102 in a global population of such patients. METHODS: In this double-blind study, we randomly assigned 800 patients, in a 2:1 ratio, to receive TAS-102 or placebo. The primary end point was overall survival. RESULTS: The median overall survival improved from 5.3 months with placebo to 7.1 months with TAS-102, and the hazard ratio for death in the TAS-102 group versus the placebo group was 0.68 (95% confidence interval [CI], 0.58 to 0.81; P<0.001). The most frequently observed clinically significant adverse events associated with TAS-102 were neutropenia, which occurred in 38% of those treated, and leukopenia, which occurred in 21%; 4% of the patients who received TAS-102 had febrile neutropenia, and one death related to TAS-102 was reported. The median time to worsening performance status (a change in Eastern Cooperative Oncology Group performance status [on a scale of 0 to 5, with 0 indicating no symptoms and higher numbers indicating increasing degrees of disability] from 0 or 1 to 2 or more) was 5.7 months with TAS-102 versus 4.0 months with placebo (hazard ratio, 0.66; 95% CI, 0.56 to 0.78; P<0.001). CONCLUSIONS: In patients with refractory colorectal cancer, TAS-102, as compared with placebo, was associated with a significant improvement in overall survival. (Funded by Taiho Oncology-Taiho Pharmaceutical; RECOURSE ClinicalTrials.gov number, NCT01607957.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Third-line treatment options are limited to regorafenib and trifluridine–tipiracil, which have extended median overall survival by less than 2 months over placebo and have been associated with a low response rate (<2%) and median progression-free survival of approximately 2 months, outcomes that highlight the need for new approaches.15,16”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [16]
In the citing paper
“Findings in the monotherapy cohort also compared favorably with the results of a trial of regorafenib (another third-line treatment) involving 505 patients, who had a response of 1.0%, progression-free survival of 1.9 months, and overall survival of 6.4 months.15,16”
From Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C (2023) · cites this paper as [16]
In the citing paper
“As described in the drug package insert, the efficacy and safety have not been established in the primary or secondary treatments [99, 100].”
From Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2018) · cites this paper as [100]
In the citing paper
“Nevertheless, single-agent garsorasib and the combination of garsorasib and cetuximab achieved considerable ORRs of 19.2% and 45.2%, and a trend toward prolonged PFS and OS, as compared with the standard-of-care includes regorafenib and trifluridine/tipiracil, which demonstrated an ORR of 1.0% and 1.6%, respectively.30,31”
In the citing paper
“The phase 3 RECOURCE trial evaluated TAS-102 vs. placebo in metastatic CRC patients refractory to standard chemotherapies [44]. TAS-102 significantly improved mOS to 7.1 months compared to 5.3 months with placebo (HR for death: 0.68, 95% CI 0.58–0.81).”
From RAS Mutations in Advanced Colorectal Cancer: Mechanisms, Clinical Implications, and Novel Therapeutic Approaches (2025) · cites this paper as [44]
1 more claim about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Van Cutsem, E., Cervantes, A., Nordlinger, B., & Arnold, D. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu260 · Cited by 1,167
Systemic Therapy for Colorectal Cancer
Meyerhardt, J. A., & Mayer, R. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmra040958 · Cited by 1,043
Self-citationSystemic Therapy for Colorectal Cancer
Varghese, A. M. (2019) · DeckerMed CGSO Case-Based Reviews · doi:10.2310/cgso.16189 · Cited by 883
Use of Statins and the Risk of Death in Patients With Prostate Cancer
Yu, O., Eberg, M., Benayoun, S., Aprikian, A., Batist, G., Suissa, S., & Azoulay, L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.49.4757 · Cited by 659
Yoshino, T., Mizunuma, N., Yamazaki, K., Nishina, T., Komatsu, Y., Baba, H., Tsuji, A., Yamaguchi, K., Muro, K., Sugimoto, N., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70345-5 · Cited by 326
Self-citationFukushima, M., Suzuki, N., Emura, T., Yano, S., Kazuno, H., Tada, Y., Yamada, Y., & Asao, T. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(00)00253-7 · Cited by 239
Tanaka, N., Sakamoto, K., Okabe, H., Fujioka, A., Yamamura, K., Nakagawa, F., Nagase, H., Yokogawa, T., Oguchi, K., Ishida, K., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3487 · Cited by 149
Emura, T., Suzuki, N., Yamaguchi, M., Ohshimo, H., & Fukushima, M. (2004) · International Journal of Oncology · doi:10.3892/ijo.25.3.571 · Cited by 120
A novel antimetabolite, TAS-102 retains its effect on FU-related resistant cancer cells
Emura, T., Murakami, Y., Nakagawa, F., Fukushima, M., & Kitazato, K. (2004) · International Journal of Molecular Medicine · doi:10.3892/ijmm.13.4.545 · Cited by 104
Research works printed but not linked: 6
- Sobrero A, 2000, Semin Oncol, 27, 72
- Emura T, 2004, Int J Mol Med, 13, 545
- Emura T, 2004, Int J Oncol, 25, 571
- Heidelberger C, 1964, Cancer Res, 24, 1979
- Heidelberger C, 1965, Cancer Res, 25, 377
- Dexter DL, 1972, Cancer Res, 32, 247
Cited by
Items 401–500 of 1,000
Tabernero, J., Taieb, J., Fakih, M., Prager, G. W., Van Cutsem, E., Ciardiello, F., Mayer, R. J., Amellal, N., Skanji, D., Calleja, E., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102945 · Cited by 18
“20 Subsequently, FTD/TPI in combination with bevacizumab was approved based on data from the randomized phase III SUNLIGHT study, which showed statistically signi fi cant improvements in overall survival (OS; primary endpoint) and progression-free survival (PFS; secondary endpoint) with FTD/TPI plus…”
BackgroundMethodSelf-citationScott, A. J., Basu Mallick, A., Dotan, E., Cohen, S. J., Gold, P. J., Hochster, H. S., Subramaniam, S., Barzi, A., Watts, G. S., Blatchford, P. J., et al. (2022) · Cancer Research Communications · doi:10.1158/2767-9764.crc-22-0169 · Cited by 18
“1194 Cancer Res Commun; 2(10) October 2022 https://doi.”
BackgroundReal-world Safety and Efficacy of Raltitrexed in Patients With Metastatic Colorectal Cancer
Batra, A., Rigo, R., Hannouf, M. B., & Cheung, W. Y. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2020.09.006 · Cited by 21
Yoshino, T., Cutsem, E. V., Li, J., Shen, L., Kim, T. W., Sriuranpong, V., Xuereb, L., Aubel, P., Fougeray, R., Cattan, V., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100511 · Cited by 19
Self-citationAlruwaili, M., Zonneville, J., Naranjo, M. N., Serio, H., Melendy, T., Straubinger, R. M., Gillard, B. M., Foster, B. A., Rajan, P., Attwood, K. M., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101434 · Cited by 21
A novel antimetabolite: TAS-102 for metastatic colorectal cancer
Miyamoto, Y., Lenz, H., & Baba, H. (2015) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2016.1133285 · Cited by 20
Self-citationSugita, K., Kawakami, K., Yokokawa, T., Sugisaki, T., Takiguchi, T., Aoyama, T., Suzuki, K., Suenaga, M., Yamaguchi, K., Inoue, A., et al. (2016) · Oncology · doi:10.1159/000448717 · Cited by 21
Unseld, M., Drimmel, M., Siebenhüner, A. R., Gleiß, A., Bianconi, D., Kieler, M., Scheithauer, W., Winder, T., & Prager, G. W. (2018) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2018.05.012 · Cited by 18
Metastatic Colorectal Cancer: Therapeutic Options for Treating Refractory Disease
Parmar, A., Chan, K., & Ko, Y. J. (2019) · Current Oncology · doi:10.3747/co.26.5575 · Cited by 20
Javaid, S., Shaikh, M., Fatima, N., & Choudhary, M. I. (2019) · PLoS ONE · doi:10.1371/journal.pone.0225056 · Cited by 18
Karani, A., Felismino, T. C., Diniz, L. A., de Macêdo, M. P., Silva, V. S. E., & de Mello, C. A. L. (2020) · ecancermedicalscience · doi:10.3332/ecancer.2020.1069 · Cited by 18
Peng, Z., Hou, X., Huang, Y., Xie, T., & Hua, X. (2020) · BMC Cancer · doi:10.1186/s12885-020-07486-w · Cited by 20
Saif, M. W. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s264156 · Cited by 21
The Role of BRAF in Metastatic Colorectal Carcinoma–Past, Present, and Future
Djanani, A. M., Eller, S., Öfner, D., Troppmair, J., & Maglione, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239001 · Cited by 20
Kamiimabeppu, D., Osumi, H., Shinozaki, E., Ooki, A., Wakatsuki, T., Yoshino, K., Sato, T., Nakayama, I., Ogura, M., Takahari, D., et al. (2021) · Oncology Letters · doi:10.3892/ol.2021.13044 · Cited by 20
Suzuki, N., Nakagawa, F., Matsuoka, K., & Takechi, T. (2016) · Oncology Reports · doi:10.3892/or.2016.5208 · Cited by 18
Taniguchi, H., Iwasa, S., Yamazaki, K., Yoshino, T., Kiryu, C., Naka, Y., Liew, E. L., & Sakata, Y. (2017) · Cancer Science · doi:10.1111/cas.13227 · Cited by 17
Self-citationZhang, X., Di, Y., Wang, Y., Qin, J., Ye, L., Wen, X., Ke, Z., Wang, Z., & He, W. (2025) · The EMBO Journal · doi:10.1038/s44318-025-00416-1 · Cited by 24
Christenson, E. S., Ho, W. J., Shu, D. H., Durham, J. N., Brancati, M., Bruning, H. D., Petrie, S., Wang, H., Lu, J., Bever, K. M., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-0002 · Cited by 18
Bando, H., Watanabe, J., Takahashi, Y., Kotaka, M., Matsuhashi, N., Oki, E., Komatsu, Y., Shiozawa, M., Hirata, K., Miyamoto, Y., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04428-0 · Cited by 24
Self-citationFernandes, G. D. S., Braghiroli, M. I., Artioli, M., Paterlini, A. C. C. R., Teixeira, M. C., Gumz, B. P., Girardi, D. M., Braghiroli, O. F. M., Costa, F. P., & Hoff, P. M. (2017) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-017-0001-3 · Cited by 17
Lago, N. M., Chuclá, T. C., de Castro, B. A., Ponte, R. V., Rendo, C. R., Gomez-Randulfe, I., Díaz, S. S., Graña, B., Gómez, J. D. L. C., Fernández, F. B., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-18871-9 · Cited by 18
TAS-102 for the treatment of metastatic colorectal cancer
Salvatore, L., Rossini, D., Moretto, R., Cremolini, C., Schirripa, M., Antoniotti, C., Marmorino, F., Loupakis, F., Falcone, A., & Masi, G. (2015) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.2015.1105746 · Cited by 17
Self-citationBianchi, A. S., Amatu, A., Bonazzina, E. F., Stabile, S., Giannetta, L. G., Cerea, G., Schiavetto, I., Bencardino, K. B., Funaioli, C., Ricotta, R., et al. (2017) · Targeted Oncology · doi:10.1007/s11523-017-0505-6 · Cited by 17
Guadagni, S., Fiorentini, G., Simone, M. D., Masedu, F., Zoras, O., Mackay, A. R., Sarti, D., Papasotiriou, I., Apostolou, P., Catarci, M., et al. (2019) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-019-03046-3 · Cited by 19
Iwasa, S., Okita, N. T., Kuchiba, A., Ogawa, G., Kawasaki, M., Nakamura, K., Shoji, H., Honma, Y., Takashima, A., Kato, K., et al. (2020) · ESMO Open · doi:10.1136/esmoopen-2020-000776 · Cited by 22
Rossini, D., Lonardi, S., Antoniotti, C., Santini, D., Tomasello, G., Ermacora, P., Germani, M. M., Bergamo, F., Ricci, V., Caponnetto, S., et al. (2020) · British Journal of Cancer · doi:10.1038/s41416-020-01089-9 · Cited by 18
Self-citationKuramochi, H., Yamada, T., Yoshida, Y., Matsuda, A., Kamiyama, H., Kosugi, C., Ishibashi, K., Fukazawa, A., Ihara, K., Sonoda, H., et al. (2021) · Anticancer Research · doi:10.21873/anticanres.15098 · Cited by 17
Weiss, L., Karthaus, M., Riera‐Knorrenschild, J., Kretzschmar, A. K., Welslau, M., Vehling‐Kaiser, U., Pelz, H., Ettrich, T. J., Hess, J., Reisländer, T., et al. (2022) · ESMO Open · doi:10.1016/j.esmoop.2022.100391 · Cited by 18
Kagawa, Y., Shinozaki, E., Okude, R., Tone, T., Kunitomi, Y., & Nakashima, M. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101614 · Cited by 18
New developments and standard of care in the management of advanced gastric cancer
Depotte, L., Palle, J., Rasola, C., Broudin, C., Afrăsânie, V.-A., Mariani, A., & Zaanan, A. (2023) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2023.102245 · Cited by 18
Abdel-Rahman, O. M., Elhalawani, H. M., & Essam-Eldin, S. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2016.1105959 · Cited by 17
Kwakman, J. J. M., Baars, A., van Zweeden, A. A., de Mol, P., Koopman, M., Kok, W. E. M., & Punt, C. J. A. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.05.022 · Cited by 17
Mauri, G., Varano, G. M., Vigna, P. D., Bonomo, G., Monfardini, L., Zampino, M. G., Ravenda, P. S., & Orsi, F. (2018) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-018-2017-x · Cited by 17
Tanioka, H., Asano, M., Yoshida, R., Waki, N., Uno, F., Ishizaki, M., Yamashita, K., Morishita, Y., & Nagasaka, T. (2018) · Oncology Letters · doi:10.3892/ol.2018.9127 · Cited by 17
S-1 plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial
Chen, Y., Wu, J., Cheng, K., Li, Z., Luo, D., Qiu, M., Gou, H., Yi, C., Li, Q., Wang, X., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0901 · Cited by 17
Osumi, H., Takashima, A., Ooki, A., Yoshinari, Y., Wakatsuki, T., Hirano, H., Nakayama, I., Okita, N., Sawada, R., Ouchi, K., et al. (2023) · Translational Oncology · doi:10.1016/j.tranon.2023.101718 · Cited by 16
Zhao, W. (2024) · American Journal of Cancer Research · doi:10.62347/xkuj3012 · Cited by 17
Li, C., Wei, Y., & Lei, J. (2025) · npj Systems Biology and Applications · doi:10.1038/s41540-025-00513-1 · Cited by 22
Yuan, Y., Deng, Y., Jin, Y., Guo, Z., Pan, Y., Wang, C., Wang, Z., Hu, Y., Hua, D., Meng, X., et al. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02315-7 · Cited by 22
Miyamoto, Y., Schirripa, M., Suenaga, M., Cao, S., Zhang, W., Okazaki, S., Berger, M. D., Matsusaka, S., Yang, D., Ning, Y., et al. (2020) · PLoS ONE · doi:10.1371/journal.pone.0239439 · Cited by 17
Self-citationStavraka, C., Pouptsis, A., Synowiec, A., Angelis, V., Satterthwaite, L., Khan, S., Chauhan, M., Holden, C., Young, S., Karampera, C., et al. (2021) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2021.09.009 · Cited by 18
Evaluation of Fruquintinib in the Continuum of Care of Patients with Colorectal Cancer
Lavacchi, D., Roviello, G., Guidolin, A., Romano, S., Venturini, J., Caliman, E., Vannini, A., Giommoni, E., Pellegrini, E., Brugia, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065840 · Cited by 21
Eng, C., Dasari, A. N., Lonardi, S., García‐Carbonero, R., Élez, E., Yoshino, T., Sobrero, A. F., Yao, J. C., Alfonso, P. G., Kocsis, J., et al. (2025) · The Oncologist · doi:10.1093/oncolo/oyae360 · Cited by 18
Self-citationEdahiro, K., Iimori, M., Kobunai, T., Morikawa, T., Miura, D., Kataoka, Y., Niimi, S., Wakasa, T., Saeki, H., Oki, E., et al. (2018) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-17-0686 · Cited by 16
Montés, A. F., Rivera, F. V., Lago, N. M., Rúa, M. C., Castiñeiras, A. C., Villarroel, P. G., Gómez, J. D. L. C., Méndez, J. C., Fernández, M. S., Folgar, S. C., et al. (2019) · Clinical & Translational Oncology · doi:10.1007/s12094-019-02130-x · Cited by 17
Ohashi, S., Kikuchi, O., Nakai, Y., Ida, T., Saito, T., Kondo, Y., Yamamoto, Y., Mitani, Y., Vu, T. H. N., Fukuyama, K., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0918 · Cited by 18
DNA Replication Stress Induced by Trifluridine Determines Tumor Cell Fate According to p53 Status
Kataoka, Y., Iimori, M., Fujisawa, R., Morikawa, T., Niimi, S., Wakasa, T., Saeki, H., Oki, E., Miura, D., Tsurimoto, T., et al. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-1051 · Cited by 18
Ogata, M., Kotaka, M., Ogata, T., Hatachi, Y., Yasui, H., Kato, T., Tsuji, A., & Satake, H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0234314 · Cited by 16
Zhang, Q., Chen, M., Wang, Z., Qi, C., Cao, Y., Zhang, J., Peng, Z., Wang, X., Lu, M. S., Shen, L., et al. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.01.007 · Cited by 21
Lang, J., Leal, A. D., Marín‐Jiménez, J. A., Hartman, S. J., Shulman, J., Navarro, N. M., Lewis, M. S., Capasso, A., Bagby, S. M., Yacob, B. W., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.877635 · Cited by 17
de Moraes, F. C. A., Pessôa, F. D. D. L., Ribeiro, C. H. D. D. C., Fernandes, M. R., Burbano, R. M. R., & dos Santos, N. P. C. (2024) · BMC Cancer · doi:10.1186/s12885-024-12447-8 · Cited by 18
Sforza, V., Martinelli, E., Cardone, C., Martini, G., Napolitano, S., Vitiello, P. P., Vitale, P., Zanaletti, N., Reginelli, A., Bisceglie, M. D., et al. (2017) · ESMO Open · doi:10.1136/esmoopen-2017-000229 · Cited by 16
Integrated safety summary for trifluridine/tipiracil (TAS-102)
Falcone, A., Ohtsu, A., Cutsem, E. V., Mayer, R. J., Buscaglia, M., Bendell, J. C., Kopetz, S., Bebeau, P., & Yoshino, T. (2017) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000000554 · Cited by 16
Self-citationGao, Y., Li, J., Zhang, H., Zhang, Y., Qian, S., Zhu, X., Hong, L., Xie, L., Fu, Q., Bao, X., et al. (2026) · Nature Cancer · doi:10.1038/s43018-026-01124-3 · Cited by 20
Lu, Y., Pan, W., Deng, S., Dou, Q.-Y., Wang, X.-X., An, Q., Wang, X., Ji, H., Hei, Y., Chen, Y., et al. (2023) · Pharmaceuticals · doi:10.3390/ph16040510 · Cited by 17
Spiekman, I. A. C., Zeverijn, L. J., Geurts, B. S., Verkerk, K., Mohammad, S. F. H., van der Noort, V., Roepman, P., de Leng, W. W. J., Jansen, A. M. L., Gootjes, E. C., et al. (2024) · European Journal of Cancer · doi:10.1016/j.ejca.2024.113988 · Cited by 16
HER2-Positive Metastatic Colorectal Cancer
Robinson, H. R., Messersmith, W. A., & Lentz, R. W. (2024) · Current Treatment Options in Oncology · doi:10.1007/s11864-024-01183-7 · Cited by 18
Asano, J., Sugano, H., Murakami, H., Noguchi, A., Ando, Y., & Uyama, Y. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.3540 · Cited by 15
Kimura, M., Usami, E., Iwai, M., Go, M., Teramachi, H., & Yoshimura, T. (2016) · Molecular and Clinical Oncology · doi:10.3892/mco.2016.1020 · Cited by 15
MicroRNA profiles involved in trifluridine resistance
Tsunekuni, K., Konno, M., Asai, A., Koseki, J., Kobunai, T., Takechi, T., Doki, Y., Mori, M., & Ishii, H. (2017) · Oncotarget · doi:10.18632/oncotarget.18078 · Cited by 16
Chemotherapy, Still an Option in the Twenty-First Century in Metastatic Colorectal Cancer?
Eisterer, W., & Prager, G. W. (2019) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-019-02278-7 · Cited by 16
Fruquintinib and its Use in the Treatment of Metastatic Colorectal Cancer
Deng, Y., & Li, X. (2019) · Future Oncology · doi:10.2217/fon-2018-0454 · Cited by 16
Andersson, Y., Inderberg, E. M., Kvalheim, G., Herud, T. M., Engebraaten, O., Flatmark, K., Dueland, S., & Fodstad, Ø. (2019) · Acta Oncologica · doi:10.1080/0284186x.2019.1704864 · Cited by 16
Cheung, W. Y., Kavan, P., & Dolley, A. (2020) · Current Oncology · doi:10.3747/co.27.6533 · Cited by 27
Liver Transplantation for Colorectal Liver Metastases: Current Management and Future Perspectives
Puia-Negulescu, S., Lebossé, F., Mabrut, J., Muller, X., Rossignol, G., Antonini, T., Erard, D., Radenne, S., Guillet, M., Souquet, J.-C., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063093 · Cited by 16
Takushima, Y., Igarashi, A., Yoshihara, H., Shitara, K., & Doi, T. (2021) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyab086 · Cited by 15
Tabernero, J. M., Shitara, K., Zaanan, A., Doi, T., Lorenzen, S., Cutsem, E. V., Fornaro, L., Catenacci, D. V. T., Fougeray, R., Moreno, S. V., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100200 · Cited by 15
Self-citationMartini, G., Ciardiello, D., Famiglietti, V., Rossini, D., Antoniotti, C., Troiani, T., Napolitano, S., Esposito, L., Latiano, T. P., Maiello, E., et al. (2023) · Cancer Medicine · doi:10.1002/cam4.5699 · Cited by 15
Stein, A., Quidde, J., Schröder, J., Göhler, T., Tschechne, B., Valdix, A.-R., Höffkes, H., Schirrmacher-Memmel, S., Wohlfarth, T., Hinke, A., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2113-8 · Cited by 16
Kubo, A., Hashimoto, H., Takahashi, N., & Yamada, Y. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i2.887 · Cited by 15
Johnson, B., Cooke, L. S., & Mahadevan, D. (2017) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2016.09.05 · Cited by 18
Gong, J., Wu, D. Y., Chuang, J., Tuli, R., Simard, J. J. L., & Hendifar, A. E. (2017) · Clinical Therapeutics · doi:10.1016/j.clinthera.2017.09.015 · Cited by 15
A phase 1 dose-escalation study of NEO-102 in patients with refractory colon and pancreatic cancer
Beg, M. S., Azad, N. S., Patel, S. P., Torrealba, J. R., Mavroukakis, S. A., Beatson, M. A., Wang, X. P., Arlen, P. M., & Morse, M. A. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3108-5 · Cited by 15
Modest, D. P., Fakih, M., Salvatore, L., Esaki, T., Páez, D., Taïeb, J., Karamouzis, M. V., Ruíz‐García, E., Kim, T. W., Kuboki, Y., et al. (2025) · The Lancet Oncology · doi:10.1016/s1470-2045(25)00352-3 · Cited by 16
Advances in Targeting HER2 across Cancer Subtypes: A Pan-Tumor Approach
Adesoye, T., Dumbrava, E. E. I., Raghav, K. P. S., Şahin, A. A., Chen, H., Lee, S. S., Javle, M. M., Pant, S., Alhalabi, O., Le, X., et al. (2025) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-25-1982 · Cited by 21
Takahashi, M., Sakamoto, Y., Ohori, H., Tsuji, Y., Kuroki, M., Kato, S., Otsuka, K., Komine, K., Takahashi, M., Takahashi, S. I., et al. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-021-04277-3 · Cited by 15
Regorafenib in Refractory Metastatic Colorectal Cancer: A Multi-Center Retrospective Study
Xu, D., Liu, Y., Tang, W., Xu, L., Liu, T., Jiang, Y., Zhou, S., Qin, X., Li, J., Zhao, J., et al. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.838870 · Cited by 14
Hamers, P. A. H., Vink, G. R., Elferink, M. A. G., Stellato, R. K., Dijksterhuis, W. P. M., Punt, C. J. A., Koopman, M., May, A. M., Beerepoot, L. V., Creemers, G., et al. (2022) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2022.03.002 · Cited by 14
Udagawa, S., Ooki, A., Shinozaki, E., Fukuda, K., Yamaguchi, K., & Osumi, H. (2023) · Cancers · doi:10.3390/cancers15051473 · Cited by 14
Voutsadakis, I. A. (2023) · Current Oncology · doi:10.3390/curroncol30060397 · Cited by 14
Germani, M. M., Vetere, G., Santamaria, F., Intini, R., Ghelardi, F., Bensi, M., Boccaccino, A., Minelli, A., Carullo, M., Ciracì, P., et al. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102996 · Cited by 16
Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer
Lo, L. L., Patel, D., Townsend, A. R., & Price, T. J. (2015) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2015.1112787 · Cited by 15
Gong, J., Chen, Y., Yang, L., Pillai, R. K., Shirasawa, S., & Fakih, M. (2017) · Anticancer Research · doi:10.21873/anticanres.11634 · Cited by 18
Skuja, E., Geriņa-Bērziņa, A., Hegmane, A., Zvirbule, Z., Vecvagare, E., & Purkalne, G. (2018) · Molecular and Clinical Oncology · doi:10.3892/mco.2018.1600 · Cited by 14
Vaflard, P., Éderhy, S., Torregrosa, C., André, T., Cohen, R., & López‐Trabada, D. (2018) · Bulletin du Cancer · doi:10.1016/j.bulcan.2018.05.005 · Cited by 16
Real-World Use of Trifluridine/Tipiracil for Patients with Metastatic Colorectal Cancer in Canada
Samawi, H. H., Brezden‐Masley, C., Afzal, A. R., Cheung, W. Y., & Dolley, A. (2019) · Current Oncology · doi:10.3747/co.26.5107 · Cited by 14
Moriwaki, T., Fukuoka, S., Masuishi, T., Takashima, A., Kumekawa, Y., Kajiwara, T., Yamazaki, K., Esaki, T., Makiyama, A., Denda, T., et al. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01600-0 · Cited by 14
Self-citationIs There an Optimal Choice in Refractory Colorectal Cancer? A Network Meta-Analysis
Gardini, A. C., Vagheggini, A., Gelsomino, F., Spallanzani, A., Ulivi, P., Orsi, G., Rovesti, G., Andrikou, K., Tamburini, E., Scartozzi, M., et al. (2020) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2019.10.001 · Cited by 15
Colorectal Cancer Care in the Age of Coronavirus: Strategies to Reduce Risk and Maintain Benefit
Marshall, J. L., Yarden, R. I., & Weinberg, B. A. (2020) · Colorectal Cancer · doi:10.2217/crc-2020-0010 · Cited by 14
Shahzad, S. A., Sarfraz, A., Yar, M., Khan, Z. A., Naqvi, S. A. R., Naz, S., Khan, N. A., Farooq, U., Batool, R., & Ali, M. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103876 · Cited by 15
Kashiwa, M., & Matsushita, R. (2020) · Clinical Therapeutics · doi:10.1016/j.clinthera.2020.05.014 · Cited by 14
Pollack, M. L. H., Keating, K. N., Wissinger, E., Jackson, L., Sarnes, E., & Cuffel, B. J. (2020) · Current Medical Research and Opinion · doi:10.1080/03007995.2020.1847057 · Cited by 17
Drug Holidays and Overall Survival of Patients with Metastatic Colorectal Cancer
Garattini, S. K., Basile, D., Bonotto, M., Ongaro, E., Porcu, L., Corvaja, C., Cattaneo, M., Andreotti, V. J., Lisanti, C., Bertoli, E., et al. (2021) · Cancers · doi:10.3390/cancers13143504 · Cited by 14
Alfonso, P. G., Martín, A. J. M., Jiménez-Castro, J., Jiménez‐Fonseca, P., Pericay, C., Longo-Muñoz, F., Reyna-Fortes, C., Argilés, G., González-Astorga, B., Gómez-Reina, M. J., et al. (2021) · Cancers · doi:10.3390/cancers13184514 · Cited by 14
Su, Y., Tsai, K., Chiu, T., Lin, Y., Lee, K., Lu, C., Chen, H., Wu, C., & Hsu, H. (2021) · Cancers · doi:10.3390/cancers13205080 · Cited by 18
Gruijs, M., Braster, R., Overdijk, M. B., Hellingman, T., Verploegen, S. A. B. W., Korthouwer, R., van der Wilk, B. J., Parren, P. W. H. I., van der Vliet, H. J., Bögels, M., et al. (2022) · Journal of Oncology · doi:10.1155/2022/3577928 · Cited by 15
Oncological Treatment-Related Fatigue in Oncogeriatrics: A Scoping Review
André, L., Antherieu, G., Boinet, A., Bret, J., Gilbert, T., Boulahssass, R., & Falandry, C. (2022) · Cancers · doi:10.3390/cancers14102470 · Cited by 15
Malami, I., Abdul, A. B., Abdullah, R., Kassim, N. B., Waziri, P. M., & Etti, I. C. (2016) · Molecules · doi:10.3390/molecules21040417 · Cited by 15
Phase 1 study of cardiac safety of TAS-102 in patients with advanced solid tumors
Bendell, J. C., Patel, M. R., Yoshida, K., Seraj, J., Weaver, R., Lemech, C., Todaro, T. G., Pant, S., & Arkenau, H. (2016) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-016-3031-9 · Cited by 14
Metadata
- Authors
- Mayer, R. J., Van Cutsem, E., Falcone, A., Yoshino, T., Garcia-Carbonero, R., Mizunuma, N., Yamazaki, K., Shimada, Y., Tabernero, J., Komatsu, Y., Sobrero, A., Boucher, E., Peeters, M., Tran, B., Lenz, H.-J., Zaniboni, A., Hochster, H., Cleary, J. M., Prenen, H., Benedetti, F., Mizuguchi, H., Makris, L., Ito, M., & Ohtsu, A.
- Affiliations
- University of Pisa (IT)
- National Cancer Center Hospital East (JP)
- Centre Eugène Marquis (FR)
- The Royal Melbourne Hospital (AU)
- USC Norris Comprehensive Cancer Center (US)
- Yale Cancer Center (US)
- Taiho Oncology (United States) (US)
- Ospedale Policlinico San Martino (IT)
- Antwerp University Hospital (BE)
- University of Southern California (US)
- Fondazione Poliambulanza Istituto Ospedaliero (IT)
- Dana-Farber Cancer Institute (US)
- KU Leuven (BE)
- Taiho Pharmaceutical (Japan) (JP)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-05-14
- Volume
- 372
- Issue
- 20
- Pages
- 1909-1919
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W242040007
- Semantic Scholar
- 3d08304a7bda1c2d5aa4ab9b3aa96bc534c22f58
- Cited by
- 1,431
- References
- 20
- Citations by year
- 2026: 97 · 2025: 136 · 2024: 165 · 2023: 145 · 2022: 150 · 2021: 138 · 2020: 150 · 2019: 112 · 2018: 115 · 2017: 116 · 2016: 79 · 2015: 27
- FWCI
- 49.50
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Colorectal Cancer Treatments and Studies
- Health Sciences › Medicine › Oncology › Colorectal Cancer Surgical Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Cancer therapeutics and mechanisms
- Keywords
- trifluridine/tipiracil, trifluridine, tipiracil, metastatic colorectal cancer, refractory colorectal cancer, oral chemotherapy, overall survival, neutropenia, leukopenia, febrile neutropenia, performance status, drug safety
- MeSH terms
- Adenocarcinoma, Adult, Aged, Aged, 80 and over, Double-Blind Method, Drug Combinations, Female, Humans, Male, Middle Aged, Neoplasm Metastasis, Pyrrolidines, Thymine, Trifluridine, Uracil, Colorectal Neoplasms, Proportional Hazards Models, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.